Loading chart...
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| 24 horas | 5 days | 1 mes | YTD | 1 año | Histórico |
|---|---|---|---|---|---|
A la baja 0.60 por ciento | Al alza 2.52 por ciento | Al alza 4.57 por ciento | Al alza 21.76 por ciento | Al alza 31.47 por ciento | Al alza 1714.48 por ciento |
